Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer

Table 3 The associations of KRAS and BRAF mutations and MSI to the risk of recurrence and dissemination in patients with colon cancer

	Disease stage II and III				Disseminated^¥	Non disseminated^β	Odds ratio (95% Confidence interval)	P
	Recurrence	No recurrence	Odds ratio (95% Confidence interval)	P	Disseminated^¥	Non disseminated^β	Odds ratio (95% Confidence interval)	P
n	42	53			68	53
KRAS
Mutation	18	14	2.09 (0.88-4.96)	0.092	34	14	2.75 (1.28-6.04)	0.009
Wild type	24	39			34	39
BRAF
Mutation	6	18	0.32 (0.16-0.91)	0.034	10	18	0.34 (0.14-0.81)	0.013
Wild type	36	35			58	35
MSI
MSI	5	17	0.29 (0.10-0.86)	0.027	7	17	0.24 (0.09-0.64)	0.005
MSS	37	36			61	36
MSS only
KRAS
Mutation	18	13	0.95 (0.35-2.58)	0.279	33	13	2.08 (0.89-4.86)	0.087
Wild type	19	23			28	23
BRAF
Mutation	2	5	0.35 (0.06-1.96)	0.261	5	5	0.55 (0.15-2.06)	0.492
Wild type	35	31			56	31
KRAS wild type only
MSI
MSI	5	16	0.38 (0.12-1.22)	0.168	6	16	0.31 (0.10-0.91)	0.041
MSS	19	23			28	23
BRAF
Mutation	6	18	0.39 (0.13-1.19)	0.115	10	18	0.49 (0.18-1.28)	0.142
Wild type	18	21			24	21
BRAF wild type only
MSI
MSI	1	4	0.22 (0.02-2.09)	0.198	2	4	0.28 (0.04-1.60)	0.194
MSS	35	31			56	31
KRAS
Mutation	18	14	1.50 (0.59-3.84)	0.397	34	14	2.13 (0.90-4.99)	0.082
Wild type	18	21			24	21
MSI and BRAF*
BRAF wild type + MSS	35	31	3.55 (1.33-9.44)	0.013	56	31	3.31 (1.45-7.59)	0.004
BRAF mutation + MSS	2	5	0.48 (0.09-2.61)	0.459	5	5	0.76 (0.21-2.78)	0.747
BRAF mutation + MSI	4	13	0.32 (0.10-1.08)	0,050	5	13	0.24 (0.08-0.74)	0.011
BRAF wild type + MSI	1	4	0.30 (0.03-2.78)	0.379	2	4	0.37 (0.07-2.11)	0.403

^βNon-disseminated: Disease stages II and III without recurrence; ^¥Disseminated: Disease stages II and III with recurrence and stage IV.
*The comparison of each subgroup is made with all other groups.

ISSN: 1471-2407